65,437 trials
Plaque Psoriasis · Psoriasis · Skin Diseases
Primary: Percentage of Subjects Achieving a Minimum 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI-75) at End-of-treatment (EOT) — 11.8; 22.0; 7.8 %…
Migraine
Primary: Time to Headache Pain Freedom — 4.0; 9.0 hours — p=0.0006
Reduction in Severity of Skin Scarring
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 8; 0 Participants
Non-Neoplastic Hematologic and Lymphocytic Disorder
Primary: Preliminary Efficacy — 83; 10 Participants
HIV/AIDS
Primary: Plasma Concentration of Tenofovir (TFV) — 0; 0; 0; 0 ng/mL
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: CR Rate — 42; 55; 134; 18 Participants
Melanoma
Primary: Comparison of Immune Responses of Vaccine+R848 to Vaccine Alone
Adenovirus Infection
Primary: Number of Participants With All-Cause Mortality — 9; 27; 8 Participants
Dementia · Caregivers · Neurodegenerative Diseases
Primary: Zarit Burden Inventory — 2.0; -0.4; 1.6 score on a scale
Generalized Pustular Psoriasis · Erythrodermic Psoriasis
Primary: Maintenance Dosing Period: Number of Participants Who Improved Global Improvement Score (GIS) at Least 1 Point From Week 12 Through Week 20 and With ≤2 of GIS — 1; 0…
Nicotine Dependence
Primary: Biochemically-confirmed 30-day Continuous Smoking Abstinence — 5; 3; 18; 5 Participants
Myasthenia Gravis, Generalized
Primary: Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results — 4.96; 3.86; 6.14…
Thrombotic Thrombocytopenic Purpura
Primary: Incidence of the Composite Primary Outcome of Exacerbation or Refractory TTP — 2; 0 Participants
Schizophrenia
Primary: P50 Sensory Gating — 41.4; 80.2 percentage
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) of Racemic-Praziquantel (Rac-PZQ) — 421; 415; 425; 459 nanogram per milliliter (ng/mL)